NRx Pharmaceuticals Inc.’s recently made public that its Chief Scientist Javitt Jonathan C acquired Company’s shares for reported $33000.0 on Aug 23. In the deal valued at $0.33 per share,100,000 shares were bought. As a result of this transaction, Javitt Jonathan C now holds 446,332 shares worth roughly $ 0.13 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Javitt Jonathan C bought 200,000 shares, generating $64,400 in total proceeds. Upon buying the shares at $0.32, the Chief Scientist now owns 346,332 shares.
Before that, Willard Stephen H bought 50,000 shares. NRx Pharmaceuticals Inc. shares valued at $58,500 were divested by the CHIEF EXECUTIVE OFFICER at a price of $1.17 per share. As a result of the transaction, Willard Stephen H now holds 50,000 shares, worth roughly $15000.0.
Price Performance Review of NRXP
On Friday, NRx Pharmaceuticals Inc. [NASDAQ:NRXP] saw its stock jump 0.98% to $0.30. On the same session, the stock had its day’s lowest price of $0.284, but rose to a high of $0.30. Over the last five days, the stock has lost -6.85%. NRx Pharmaceuticals Inc. shares have fallen nearly -73.15% since the year began. Nevertheless, the stocks have fallen -54.15% over the past one year. While a 52-week high of $1.54 was reached on 01/13/23, a 52-week low of $0.27 was recorded on 08/23/23. SMA at 50 days reached $0.3800, while 200 days put it at $0.7720. A total of 2.01 million shares were traded, compared to the trading of 1.86 million shares in the previous session.
Levels Of Support And Resistance For NRXP Stock
The 24-hour chart illustrates a support level at 0.2880, which if violated will result in even more drops to 0.2780. On the upside, there is a resistance level at 0.3040. A further resistance level may holdings at 0.3100. The Relative Strength Index (RSI) on the 14-day chart is 41.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0130, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.51%. Stochastics %K at 33.30% indicates the stock is a holding.
How much short interest is there in NRx Pharmaceuticals Inc.?
A steep rise in short interest was recorded in NRx Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -0.41 million shares to a total of 0.8 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.21 million shares. There was a decline of -51.05%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.50% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.96.
NRx Pharmaceuticals Inc. [NRXP] – Who Are The Largest Shareholders?
In filings from Armistice Capital LLC, it is revealed that the company now owns 5,636,000 shares, or roughly 8.02% of the outstanding NRXP shares.. At present, BlackRock Fund Advisors is holding 290,714 shares valued at $0.11 million. City National Rochdale LLC owned 170,000 shares of the company at the time of its most recent 13F filing, worth $66300.0.
According to FactSet, NRx Pharmaceuticals Inc.’s share price will average $9.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 2900.0 percent from its previous closing price of $0.30. Analysts expect NRx Pharmaceuticals Inc. stock to reach the higher price of $9.00, while the lowest price estimate is $9.00. However, 1 analyst have rated NRXP stock as a Buy in their predictions for 2023.